The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY 2016 Annual Meeting And The ISAP 25th Annual Meeting

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700 (formerly, ABP-700) development program will be presented at ANESTHESIOLOGY® 2016, the annual meeting of the American Society of Anesthesiologists (ASA), being held at the McCormick Place in Chicago from October 22-26, 2016 and at the International Society for Anaesthetic Pharmacology 25th Annual Meeting (ISAP) taking place at the Hyatt Regency Chicago on October 21, 2016.

Investigators will present data from the MDCO-700 Phase I clinical program and preclinical animal studies evaluating infusion optimization, safety, tolerability and pharmacokinetic and pharmacodynamic parameters at both meetings in the form of oral and poster presentations.

About MDCO-700

MDCO-700 (formerly, ABP-700), an investigational product not approved for commercial use in any market, is a novel, positive allosteric modulator of the GABA-A receptor currently being developed for the induction of general anesthesia and procedural sedation. MDCO-700 is from a family of compounds invented by Dr. Douglas Raines at the Massachusetts General Hospital.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose—to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. The Company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.

Forward Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “views” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the clinical trials for our product candidates, including MDCO-700, will advance in the clinical process on a timely basis, or at all, or succeed in achieving their specified endpoints; whether the Company is able to disclose clinical trial results on a timely basis; whether physicians, patients and other key decision makers will accept clinical trial results; whether the Company will make regulatory submissions for its product candidates on a timely basis, or at all; whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis, or at all; and such other factors as are set forth in the risk factors detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2016 , which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.